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Interleukin (IL)-4Microglia have multiple functions in cerebrovascular and neurodegenerative diseases. Regulation of microglial
function during inﬂammatory stress is important for treatment of central nervous system (CNS) diseases because
microglia secrete various substances that affect neurons and glia. MicroRNA-Let-7a (miR-Let-7a) is a tumor sup-
pressor miRNA that has been reported to target transcripts that encode proteins involved in apoptosis. In the
present study, we examined the essential role of miR-Let-7a in inﬂammatory stress by over-expressing miR-
Let-7a to investigate its role in determining the BV2microglial phenotype, a cell line often used as a model of ac-
tivated microglia. We found that inﬂammatory factors and Reactive Oxygen Species (ROS) production levels
were altered according to miR-Let-7a expression level as measured by Western blot analysis, reverse transcrip-
tion PCR, quantitative real time PCR, the measurement of nitrite (indicative of the nitric oxide (NO) pathway),
and immunocytochemistry (ICC). Our results suggest that miR-Let-7a is involved in the function of microglia
in the setting of inﬂammatory injury. In response to inﬂammation, miR-Let-7a participates in the reduction of
nitrite production and the expression of inducible nitric oxide synthase (iNOS), interleukin (IL)-6 and is involved
in increased expression of brain derived neurotrophic factor (BDNF), interleukin (IL)-10, and IL-4 in microglia.
Thus, miRNA-Let-7a could act as a regulator of the function of microglia in inﬂammation.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Microglia are derived from primitive macrophages in the yolk sac
and the resident macrophages of the central nervous system (CNS)
(Ginhoux et al., 2010). In response to any stimulus, microglia indicates
a variety of responses that includes morphological alterations (Minten
et al., 2012), migration to the site of injury (Jolivel et al., 2014; Yu
et al., 2014), and increased expression of various factors such as cyto-
kines (Kim et al., 2014; Skaper et al., 2014). Moreover, microglia trans-
form into phagocytic cells; removing dead cells, protein aggregates, and
viral pathogens (Hanisch and Kettenmann, 2007). Microglia are funda-
mentally responsible for inﬂammatory changes (Lynch, 2009). For ex-
ample, ischemic injury and oxidative stress are associated with rapid
microglia activation and inﬂammatory changes (Lynch, 2009). This
acute response is considered to be protective (Lynch, 2009). In contrast,
persistent microglial activation triggers recruitment of peripheral cells
into the brain and ﬁnally leads to chronic neuroinﬂammation (Lynch,
2009;Walker et al., 2014). Uncontrolledmicroglia activation is associat-
ed with the pathophysiology of several diseases including ischemic, Yonsei University College of
nsei University, 50 Yonsei-ro,
. This is an open access article understroke (Yrjanheikki et al., 1998), and neurodegenerative diseases such
as Alzheimer's, Parkinson's, and Huntington's diseases (Frank-Cannon
et al., 2009). Recent studies revealed that the activation states are broadly
described in terms of macrophagic responses as the classically-activated,
pro-inﬂammatory (Frankola et al., 2011; Hagar et al., 2013), neurotoxic
phenotype (M1 phenotype), and the alternatively-activated, anti-
inﬂammatory or M2 phenotype involved in phagocytosis and tissue re-
pair (Fiorentino et al., 1989; Glocker et al., 2009). Exposure of microglia
cell cultures to bacterial lipopolysaccharides (LPS) (Bhat et al., 1998;
Chao et al., 1992), tumor necrosis factor-alpha (TNF-α) (Takeuchi et al.,
2006), interferon-gamma (IFN-γ) (Meda et al., 1995), or oligomers of am-
yloid beta (Aβ) (Maezawa et al., 2011) induces theM1phenotype. On the
other hand, the alternative, M2 phenotype is neuroprotective (Hjorth
et al., 2013; Koenigsknecht-Talboo and Landreth, 2005; Mandrekar-
Colucci et al., 2012) and can be induced in primary microglial cells by
interleukins (IL)-4 and IL-13 (Freilich et al., 2013). IL-4 was found to
decrease inducible nitric oxide synthase (iNOS) activity, and superoxide
and TNF-α production in LPS-activated microglia (Chao et al., 1993;
Zhao et al., 2006). IL-4 also increases the phagocytic activity of microglia,
including theuptake of oligomeric Aβ species (Shimizu et al., 2008). In ad-
dition, IL-13 and IL-10 are secreted fromM2-phenotype microglia which
increases microglial secretion of neuroprotective transforming growth
factor beta (TGF-β) (Miron et al., 2013). M2-phenotype microglia activa-
tion leads to secretion of brain-derived neurotrophic factor (BDNF)
(Hains and Waxman, 2006; Lu et al., 2013; Ulmann et al., 2008), as wellthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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demonstrate that BDNF acts as a neuronal survival factor (Ghosh et al.,
1994; Lindvall et al., 1994).Moreover,microglial BDNF increases neuronal
tropomyosin-related kinase receptor B (trkB) phosphorylation which is a
keymediator of synaptic plasticity (Chao, 2003) and contributes to learn-
ing and memory function by promoting learning-related synapse forma-
tion (Parkhurst et al., 2013).
MicroRNAs (miRNAs) are a class of short, non-codingRNAmolecules
(19–25 nucleotides in length) that suppress target gene expression at
the post-transcriptional level through incomplete base-pairing to the
3′-untranslated region (3'UTR) of target mRNAs (Skaftnesmo et al.,
2007; Valencia-Sanchez et al., 2006). MiRNAs are transcribed from
intragenic or intergenic regions by RNA polymerase II or RNA polymer-
ase III, originating large stem-loop hairpin structures designated pri-
miRNAs (Filipowicz et al., 2008). MicroRNAs have been reported to
play critical roles in a variety of processes such as neurogenesis (Choi
et al., 2008; Kloosterman et al., 2004; Wienholds and Plasterk, 2005).
MiRNA-mediated regulation of gene expression has been associated
with various important biological processes, including inﬂammation,
apoptosis, angiogenesis, and proliferation (Arora et al., 2013; Chen
et al., 2011). Recent studies have shown that miR-155 is able to target
microglia M2 phenotype-associated genes, such as that encoding
SMAD2, a protein associated with the TGF-β pathway (Louaﬁ et al.,
2010). Also, miR-92a was recently shown to be down-regulated in
response to the activation of Toll-like Receptors (TLRs), and is necessary
to promote the production of inﬂammatory cytokines inM1-phenotype
macrophages (Lai et al., 2013). MiR-124 is involved in the secretion of
M1 phenotype-associated cytokines (Ponomarev et al., 2011). MiR-
Let7 was initially found to regulate cell proliferation and differentiation
in Caenorhabditis elegans (Reinhart et al., 2000). Let-7 is a kind ofmiRNA
found across species that is present in multiple genomic locations and
there are 10 mature Let-7 isoforms with the same seed sequence from
13 precursor sequences (Roush and Slack, 2008). MiR-Let-7a mainly
regulates anti-inﬂammatory properties through repression of speciﬁc
genes targeting downstream signaling pathways (Chen et al., 2007). It
is unknown whether miR-Let-7a plays an essential role in microglia
function under inﬂammatory conditions. In the present study,we inves-
tigated whether differentially regulated miR-Let-7a expression affects
the macrophagic phase and modulates secretion of factors associated
with the M1 or M2 phenotype of microglia under inﬂammatory
conditions.
2. Results
2.1. Microglia over-expressing Let-7a were less vulnerable to apoptotic cell
death
First of all, by TaqMan assaywe examined the change ofmiRNA level
in microglia BV2 cells under LPS stimulation andmiR-Let-7a was signif-
icantly reduced under LPS stimulated condition (Fig. 1A). This result
gave us a hint that Let-7a, a well-knownmiRNA, may involve in inﬂam-
mation by microglia BV2 cell. Under LPS, miR-Let-7a level decreased to
0.3 fold.When BV2was transfected withmiR-Let-7amimic, the level of
miR-Let-7a was over-expressed to over 3 fold. After then, to evaluate
the role of miR-Let-7a on the death ofmicroglia, we conductedWestern
blot analysis and immunochemical imaging analysis under conditions
of over-expression of miR-Let-7a. We examined the protein level
(Fig. 1B) and the immunochemistry (Fig. 1C) of cleaved caspase-3 as a
marker of mitochondrial apoptosis. Our results showed that the protein
level of cleaved caspase-3 and the number of cleaved caspase-3
immunopositive cells increased in the LPS treatment group compared
with the normal control group (Fig. 1B, C). Moreover, overexpression
of the miR-Let-7a with LPS treatment signiﬁcantly attenuated the pro-
tein level of cleaved caspase-3 and the number of cleaved caspase-3-
positive cells compared to the LPS-only treatment group (Fig. 1B, C).
Our results showed that the protein level of cleaved caspase-3 and thenumber of cleaved caspase-3 immunopositive cells increased in the
LPS treatment group compared with the normal control group
(Fig. 1B, C). MiR-Let-7a over-expression during LPS treatment signiﬁ-
cantly attenuated the protein level of cleaved caspase-3 and decreased
the number of cleaved caspase-3 immunopositive cells compared to
the LPS-only treatment group (Fig. 1B, C). Taken together, our results
suggested that miR-Let-7a suppresses LPS-induced apoptosis through
regulation of apoptosis-related gene expression.
2.2. Microglia over-expressing Let-7a present with anM2 phenotype rather
than an M1 phenotype
To check the effect of miR-Let-7a on the phenotype of microglia, we
conducted immunochemical analysis to detect CD68 as a marker of the
M1 phenotype of microglia (Fig. 2A) or a mannose receptor CD206 as a
marker of the M2 phenotype of microglia (Fig. 2B). Fig. 2A shows also
that the number of CD68-positive BV2 microglia increased whereas
over-expression of miR-Let-7a did not change the expression of CD68
in the same LPS-induced inﬂammation condition. On the contrary, our
result showed that the number of CD206-immunopositive BV2 microg-
lia decreased whereas miR-Let-7a over-expression did not change the
expression of CD206 in the same LPS-induced inﬂammation condition
(Fig. 2B). As a counter-part, these data suggest that miR-Let-7a may
affect the phenotype of microglia and promote the M2 phenotype
under inﬂammatory conditions through regulating the associated
gene expression.
2.3. Let-7a was down-regulated by LPS-inﬂammation and IL-10 and IL-4
were enhanced by Let-7a over-expression
To examine and conﬁrm the role of miR-Let-7a in regulating the in-
ﬂammatory phase, expression of IL-10, IL-4 and IL-6 were assessed by
quantitative real time RT-PCR (Fig. 3). The mRNA level of IL-10 that is
anti-inﬂammatory interleukin was signiﬁcantly decreased in LPS-
treated microglia compared with the normal control group (Fig. 3A-a).
With reverse correlation of IL-10, themRNA level of IL-6 that is a repre-
sentative pro-inﬂammatory factor was signiﬁcantly increased in LPS-
treated microglia compared with the normal control group (Fig. 3A-c).
However, the decreasing level of IL-4 was not signiﬁcant even though
the IL-4 is also an anti-inﬂammatory factor same as IL-10 (Fig. 3A-b).
Corresponding to the result of CD 206 immunohistochemistry, an anti-
inﬂammatory phase M2 marker, the expression of IL-10 was increased
in miR-Let-7a over-expressing cells with LPS treatment compared to
the normal group as well as the LPS-only treatment group (Fig. 3A-a).
In case of IL-6 expression level, over-expressing miR-Let-7a slightly at-
tenuated the level of it (Fig. 3A-c). Although the level of IL-6 was still
higher than normal, the reduced amount was signiﬁcant comparing to
LPS-only treatment. Under LPS-only treatment, IL-10 was signiﬁcantly
reduced over 5 fold (0.168 fold change), whereas IL-4 did not signiﬁ-
cantly decrease (0.76 fold change). However, when miR-Let-7a was
over-expressed, both IL-10 and IL-4 were signiﬁcantly enhanced up to
over 3.5 fold. In addition, when miR-Let-7a was over-expressed during
LPS treatment, IL-10 was increased 3.8 fold compared to the LPS-only
treated group. In contrast to IL-10, the mRNA level of IL-4 showed to
be the same, but differed only to the LPS treated microglia. To further
evaluate the role of miR-Let-7a in regulating inﬂammatory factor, we
used the miR-Let-7a mimic and also inhibitor (anti-Let-7a) and they
were transfected in BV2 cells (Fig. 3B). The level of IL-10 transcript
was signiﬁcantly improved in BV2 cells over-expressing miR-Let-7a
compared with normal while the BV2 cells down-regulating miR-Let-
7a was signiﬁcantly diminished to similar level of LPS group (Fig. 3B-
a). The IL-6 mRNA level was shown the reverse correlative pattern of
IL-10 but the down-regulating miR-Let-7a did not increased up to the
level of LPS group (Fig. 3B-b). Thus, miR-Let-7a affects the expression
of IL-10, IL-6 and IL-4 in microglia and is involved mainly in regulation
of IL-10 under inﬂammatory conditions.
Fig. 1. Changing level of miR-Let-7a and anti-apoptotic role of Let-7a. (A) The proﬁle of miR-Let-7a expression after LPS treatment was examined with TaqMan assay (left graph). The
mRNA of miR-Let-7a was detected in all groups using TaqMan RT-PCR assay (right graph). In Let-7a group, miR-Let-7a mRNAwas measured over 2 fold changes compared to the normal
control group owing to themiR-Let-7amimic treatment. In LPS treatment group, mRNA level ofmiR-Let-7a decreases over 2 fold changes compared to the normal control group. Data are
expressed asmean± S.E.M. *p b 0.05, **p b 0.001. #p b 0.05, comparison to LPS only treated group. (B)Western blotting showed that the protein level of cleaved caspase 3 was evidently
increased in LPS treatment group compared to the normal control group. The protein level of cleaved caspase 3was attenuated inmiR-Let-7a with LPS treatment group, compared to only
LPS treatment group. The bar graph shows the quantiﬁcation of cleaved caspase 3 protein in all groups. β-Actin was used as an internal control. Data are expressed as mean ± S.E.M.
*p b 0.05, **p b 0.001. #p b 0.05, comparison to LPS only treated group. (C) The expression of cleaved caspase-3 was evaluated by immunocytochemistry. This image shows that the ex-
pression of cleaved caspase-3 in the LPS treatment group was increased compared to the normal control group. MiR-Let-7a attenuated the LPS-induced increase in the number of cleaved
caspase-3 positive cells. InmiR-Let-7awith LPS treatment group, the expression of cleaved caspase-3was lower than in only LPS treatment group. The expression of cleaved caspase-3was
attenuated in miR-Let-7a treatment group under LPS induced inﬂammatory condition. Scale bar: 200 μm, cleaved caspase-3: red, 4′, 6-diamidino-2-phenylindole (DAPI): blue. Normal:
normal control group, LPS: LPS (100 nM) treatment group, Let-7a: miR-Let-7a mimic treatment group, LPS + Let-7a: miR-Let-7a mimic with LPS (100 nM) treatment group.
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To evaluate the expression of iNOS, we conducted (RT)-PCR assays,
and measured nitrite using the Griess reagent (Fig. 4). Our results
showed that LPS-induced inﬂammation leads to the increase of iNOSmRNA and the increase of nitrite production (Fig. 4A) in microglia. In
addition, miR-Let-7a over-expression decreased the production of ni-
trite and the expression of iNOS in LPS-treated microglia (Fig. 4A).
And also to check and conﬁrm the role of miR-Let-7a in iNOS and NO
production, iNOS mRNA level and NO production were measured both
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down-regulation by miRNA inhibitor (Fig. 4B). The expression level of
iNOSwas not changed inmiR-Let-7a over-expressing BV2 cells whereas
the level of it was signiﬁcantly raised up to level in LPS treated condition
(Fig. 4B-a). Corresponding to the iNOS transcript level, production level
of NO was not altered in miR-Let-7a over-expressing BV2 cells whereas
the level of it was signiﬁcantly increased up to level in LPS treated con-
dition (Fig. 4B-b). Thus,miR-Let-7amay regulate transcripts involved in
or encoding iNOS expression and may attenuate the production of ni-
trite in microglia under inﬂammatory conditions.
2.5. Upregulation of Let-7a prevented the decrease in BDNF expression
BDNF which is produced and secreted by microglial cells as well as
neuron is a crucial signaling molecule between microglia and neurons.
To examine the expression of BDNF,Western blot analysis and immuno-
cytochemistry were performed (Fig. 5). Our results showed that the ex-
pression of BDNF (Fig. 5) was signiﬁcantly decreased in LPS-treated
microglia compared with the normal control group. The expression of
BDNF was increased in miR-Let-7a over-expressing cells treated with
LPS compared to the non-over-expressing cells (Fig. 5A, B). Therefore,
miR-Let-7a may promote the expression of BDNF proteins in microglia
under inﬂammatory conditions.
3. Discussion
Our study was designed to test whether the miR-Let-7a modulates
the phenotype of microglia and microglial BDNF levels under LPS-
induced inﬂammatory conditions, which would mediate microglial
function by controlling anti-inﬂammatory factors. This study provides
twomajor ﬁndings: (1) Up-regulatedmiR-Let-7a inmicroglia increases
anti-inﬂammatory factors and protects microglia from apoptotic dam-
age; (2) Under inﬂammatory conditions, microglia over-expressing
miR-Let-7a display the M2 phenotype.
MiRNAs, regulatory molecules involved in many physiological pro-
cesses, have been shown to regulate cellular differentiation and activa-
tion of cells in the immune system (Ambros, 2004). Speciﬁcally, in the
central nervous system (CNS), miRNAs have been identiﬁed as crucial
regulators for determining cell types such as neuronal cells andmyeloid
cells (Bi et al., 2009; Johnnidis et al., 2008). One of themiRNAs,miR-124,
is expressed in normalmicroglia and also identiﬁed as a key regulator of
proliferation of microglia. Additionally, miR-124 differentiates imma-
ture CNS cells into mature cells via down-regulation of the active mi-
croglia (Ponomarev et al., 2011). Let-7A was the ﬁrst identiﬁed miRNA
and is relatively well-known. The alteration of miR-Let-7a levels has
been reported to regulate genes related to cell cycle and cell prolifera-
tion such as cyclin A2, CDC34, and E2F (Klemke et al., 2010); apoptosis
is also modulated by miR-Let-7a and mediated by caspase-3, bcl-2 and
the MAP3 kinase pathway (Mu et al., 2010). In the immune response,
it has been suggested that Let-7a is involved in post-translational regu-
lation of innate immunity and in the decrease of IL-6 and IL-10
(Ricarte-Filho et al., 2009; Trang et al., 2010).
Microglia are macrophages of the CNS and participate in innate in-
ﬂammatory responses. Microglia are heterogenic and have two distinct
phenotypes according to their activation (Freilich et al., 2013). One is
the classical M1 phenotype associated with inﬂammation and tissue
damage, and the other is an alternative M2 phenotype (Freilich et al.,
2013). MiRNAs have emerged as crucial regulators of the post-
transcriptional control of gene expression and modulators for decisiveFig. 2.Differential regulation of Let-7a onmacrophagic condition. (A) Immunoﬂuorescent stainin
microglia shows increased expression of CD206 compared to the normal control microglia. MiR
4′, 6-diamidino-2-phenylindole (DAPI): blue, CD206: red. (B) Immunoﬂuorescent staining cond
stimulated microglia shows decreased expression of CD68 compared to the normal control m
graphs present the quantity of the CD206-positive cells (left) and CD68-positive cells (right). Scascades occurring thereafter (Yao et al., 2014). The major goal of this
study was to investigate the contribution of a speciﬁc miRNA, Let-
7a, to the modulation of the microglia-mediated inﬂammatory re-
sponse. Our investigation showed that miR-Let-7a was signiﬁcantly
reduced in LPS-treated microglia BV2 cells (Fig. 1A) and indicated
that modulation of the microglia phenotypes by miR-Let-7a might
be related to triggering the inﬂammatory pathway by LPS. We
over-expressed miR-Let-7a levels by transfecting the Let-7a miRNA
mimic. Prior to modulation of inﬂammation by miR-Let-7a, we vali-
dated the effect of miR-Let-7a on apoptotic cell death (Fig. 1). In
this study, miR-Let-7a attenuated the expression of cleaved
caspase-3 in microglia in inﬂammatory conditions. The results sug-
gested that miR-Let-7a suppresses the apoptosis of microglia in re-
sponse to LPS-induced inﬂammation. Although our study could not
differentiate the possibility that over-expression of miRNA-Let-7a
caused microglial proliferation, at least microglia were less irrigated
by LPS inducing inﬂammatory condition. Also, when cells such as mi-
croglia are exposed to LPS, inﬂammation occurs as a responsive reac-
tion by increasing the macrophage 1 (M1) phase instead of
macrophage 2 (M2) phase. In our study, miR-Let-7a affected the
phenotype of microglia toward the anti-inﬂammatory M2 pheno-
type in physiologic conditions (normal state). Moreover, over-
expression of miR-Let-7a promoted the M2 phenotype in microglia
under inﬂammatory conditions (Fig. 2). These data suggest that
miR-Let-7a not only deactivates microglia but also tilts their polari-
zation from an M1 phenotype toward an M2 phenotype. This result
is consistent with the report that inactive microglia show properties
of M2 phenotype, which are important in the suppression of experi-
mental autoimmune encephalomyelitis (EAE) (Ponomarev et al.,
2007). Transfection of microglia with a miR-Let-7a mimic resulted
in down-regulation of M1-positive phenotype cells whereas the acti-
vated M2 phenotype microglia increased and was followed by up-
regulation of BDNF. Although the anti-inﬂammatory microglia M2
phenotype has been demonstrated to play an important role in the
regulation of the allergic immune responses (Freilich et al., 2013),
studies are needed to examine the mechanisms of regulation and
the beneﬁcial role of the M2 phenotype. Innate immunity is the
ﬁrst defense system against both external and internal insults in
the brain, and microglia are regarded as a decisive mediator of the
process. In a study using microglia cultures (Zhao et al., 2006), in-
ﬂammation produced by LPS increased nitric oxide (NO) and super-
oxide (O2−) levels, and interaction of IL-4 with microglial IL-4
receptors inhibited NO release. NO is one of the free radicals detected
in microglia, and over-production of NO in microglia results in
immune-mediated brain injury (Chao et al., 1992). In our study,
miR-Let-7a suppressed the production of nitrite and the expression
of iNOS in microglia treated with LPS which normally leads to an in-
crease in iNOS mRNA and protein level (Fig. 4). MiR-Let-7a may reg-
ulate the expression of iNOS and may attenuate the production of
nitrite in microglia under inﬂammatory conditions. Alternatively,
studying on translationally suppressed genes targeted by speciﬁc
miRNA, miRNAs containing let-7 family are generally implicated in
regulating TLR/NF-κB signal pathway (Mueller et al., 2014;
Choudhury and Li, 2012). SIRT1 known as Sirtuin 1 or NAD-
dependent deacetylase sirtuin-1 has been reported to promote p65
deacetylation and deacetylated p65 to inhibit NF-κB activity and
also recently to be identiﬁed a target for some kind of miRNAs (Xie
et al., 2014). Recently Let-7 miRNA family is also reported to target
SIRT1 expression: especially let-7i is harnessing SIRT1 in epithelialg conducted to checkCD206 expression known as aM2phenotypemarker. LPS stimulated
-Let-7a suppresses the expression of CD206 in LPS stimulatedmicroglia. Scale bar: 200 μm,
ucted to checkmannose receptor CD68 expression known as aM1 phenotypemarker. LPS
icroglia. MiR-Let-7a promotes the CD68 expression in LPS stimulated microglia. (C) The
cale bar: 200 μm, 4′, 6-diamidino-2-phenylindole (DAPI): blue, CD68: green.
Fig. 3. Anti-inﬂammatory role of over-expressing Let-7a in microglia under inﬂammation. (A) The mRNA level of IL-10 (a), IL-4 (b) after miR-Let-7a treatment in LPS-induced inﬂamma-
tionwasmeasured by using quantitative real time (RT)-PCR. The LPS treatment group showed lowermRNA levels of IL-10 (a), IL-4 (b) compared to the normal control group. MiR-Let-7a
with LPS treatment was almost the same IL-10 (a), IL-4 (b) mRNA levels compared to the only LPS treatment group. The LPS treatment group showed higher mRNA levels of IL-6
(c) compared to the normal control group. MiR-Let-7a with LPS treatment was slightly decreased IL-6 (c) mRNA levels compared to the only LPS treatment group. *p b 0.05, comparison
to normal control (NC). #p b 0.05, comparison to LPS only treated group. (B) ThemRNA level of IL-10 (a), IL-6 (b) aftermiR-Let-7amimic (Let7a) or inhibitor (ani-Let7a) treatment in LPS-
induced inﬂammation was measured by using quantitative real time (RT)-PCR. The LPS treatment group showed lower mRNA levels of IL-10 (a) compared to the normal control group.
Under LPS treatment,miR-Let-7a over-expressionwas shown to higher level of IL-10 thanNC, and the level of IL-10 treatedwith anti-Let-7awas converted to the level of LPS single treated
group. The LPS treatment group showedhighermRNA levels of IL-6 (b) compared to the normal control group.miR-Let-7awith LPS treatmentwas slightly decreased IL-6 (b)mRNA levels
compared to the only LPS treatment group. *p b 0.05, comparison to normal control (NC). NC: normal control group, LPS: LPS (100nM) treatment group, Let-7a: LPSwithmiR-Let-7amimic
treated group, anti-Let7a: LPS with miR-Let-7a inhibitor treated group.
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by Cryptosporidium parvum (Xie et al., 2014). We did not provide the
gene or pathway directly targeted by let-7a in our study. Referred
above reports, it might be inferred that let-7a consisted in let-7 fam-
ily involves in TLR/NF-kB pathway via targeting SIRT1.
Under LPS-induced inﬂammatory conditions, our results showed
that reduction of BDNF was prevented in BV2 microglia over-
expressing miR-Let-7a. MiR-Let-7a may promote the expression of
BDNF in microglia under inﬂammatory conditions. During inﬂamma-
tion, microglia undergo changes in cell proliferation and morphology,
and consequently synthesize and secrete both pro-inﬂammatory and
anti-inﬂammatory components (Gomes et al., 2013). The neurotrophic
factor, BDNF, has been reported to prevent axonal and neuronal damage
due to various pathological insults (Dougherty et al., 2000). BDNF is also
involved in neuro-inﬂammation via several modulators (Gomes et al.,
2013). BDNF in the CNS is supplied by immune cells and increased
GP145-TrkB has been suggested as a candidate for mediating a neuro-
protective role in multiple sclerosis (Stadelmann et al., 2002). BDNF,
which is produced and secreted by microglial cells, is a crucial signaling
molecule between microglia and neurons (Coull et al., 2005). Blocking
of this signaling pathway between microglia and neurons has beensuggested as a possible therapeutic strategy for neuropathic pain
(Coull et al., 2005). Our results also demonstrated that the effect of
miR-Let-7a over-expression on BV2 microglia-derived BDNF was not
inhibited by LPS-triggered inﬂammation. Consistent with previous re-
ports, our results imply that miR-Let-7a is involved in the anti-
inﬂammatory role of microglia under active inﬂammatory conditions.
Up-regulated miR-Let-7a boosted the transcriptional expression
level of the anti-inﬂammatory factors IL-10 and IL-4 in LPS-treated mi-
croglia. There have been previous reports examining the effects of
miRNA on microglia or neuro-inﬂammation. MicroRNA miR-124,
over-expressed in microglia, is reported to induce the M2 phenotype,
and three miR-124 precursors induced IL-4 expression on a transcrip-
tional level (Freilich et al., 2013; Ponomarev et al., 2011). Another report
found that microglia withmiR-9 enhanced pro-inﬂammatory cytokines
such as IL-1β, TNF-α, IL-6, andMCP-1, and suggested thatmiR-9was in-
volved in LPS-derivedmicroglial activation (Yao et al., 2014). In the case
of inﬂammation, the anti-inﬂammatory cytokine IL10 was preferential-
ly reduced instead of IL-4. In this study, miR-Let-7a expression led to
increases in the anti-inﬂammatory cytokines IL-10 and IL-4. When mi-
croglia over-expressing miR-Let-7a were treated with LPS, IL-10 was
signiﬁcantly increased and the transcriptional level of IL-10 increased
Fig. 4. Inﬂammatory regulation of Let-7a via iNOS. (A) (a) iNOSmRNA expression after miR-Let-7a treatment in LPS-induced inﬂammation. iNOSmRNA level was measured by using re-
verse transcription (RT)-PCR. The LPS treatment group showed highermRNA levels of iNOS compared to the normal control group. MiR-Let-7a with LPS treatment resulted in lower iNOS
mRNA levels compared to the only LPS treatment group. *p b 0.05, **p b 0.001. (b) Nitrite production from LPS-treated microglia was measured by using Griess reagent. Nitrite concen-
tration is approximately 55 μM in the LPS treatment groupwhereas upon the addition ofmiR-Let-7a, the nitrite concentrationwas 25 μM. *p b 0.05, **p b 0.01. #p b 0.05, comparison to LPS
only treated group. (B) (a) iNOSmRNA level wasmeasured by using quantitative real time (RT)-PCR. The LPS treatment group showed almost 2 fold changes highermRNA levels of iNOS
compared to the normal control group. MiR-Let-7a with LPS treatment resulted in lower iNOS mRNA levels compared to the only LPS treatment group. In anti-Let-7a treatment group,
iNOS mRNA level is the same of the normal control group. *p b 0.05, **p b 0.001. (b) Nitrite concentration is approximately 28 μM in the LPS treatment group. Upon the addition of
miR-Let-7a, the nitrite concentration decreases over 2 fold changes compared to those of the LPS treatment group. In anti-Let-7a treatment group, iNOS mRNA level is the same of the
normal control group. Data were expressed as themean± S.E.M. *p b 0.05,**p b 0.001. NC: normal control group, LPS: LPS (100 nM) treatment group, Let-7a:miR-Let-7amimic treatment
group, LPS + Let-7a: miR-Let-7a with LPS (100 nM) treatment group, anti-Let-7a: anti-miR-Let-7a treatment group.
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IL-4 was found to be unchanged compared to LPS only treatment. It
has been suggested that IL-4 is an important immuno-modulator that
can protect against microglia-derived neurotoxicity by suppressing Re-
active Oxygen Species (ROS) overproduction and release (Zhao et al.,
2006). However, our study suggests that IL-10 is more highly regulated
than IL-4 bymiR-Let-7a inmicroglia. Nevertheless, in contrast to resting
BV2 microglia, over-expressing miR-Let-7a triggered the up-regulation
of both IL-10, and IL-4 at the transcriptional level in normal microglia.
It is possible that miR-Let-7a acts on IL-10 transcription speciﬁcally,
and not on IL-4.
Although this study did not evaluate the direct protective effect of
BV2 microglia on neurons or investigate the relationship between
microglia and neurons, the results suggest a possible beneﬁcial and
novel role of miR-Let-7a in microglia. Overall, our results showed that
miR-Let-7a helped BV2 microglia to express the anti-inﬂammatory M2
phenotype by up-regulating mainly IL-10 transcription in response to
the LPS-induced inﬂammatory conditions. In conclusion, in response
to inﬂammation, miR-Let-7a represses the production of nitrite and
the expression of iNOS, IL-6 in microglia, and activates the expression
of BDNF, and anti-inﬂammatory factors such as IL-10 and IL-4. Our
study suggests that miR-Let-7a is involved in modulating the anti-
inﬂammatory function of microglia following inﬂammation.4. Experimental methods
4.1. Cell culture and drug treatment
Murine BV2 microglial cells were obtained from Prof. Eun-hye
Joe (Ajou University School of Medicine, Chronic Inﬂammatory Dis-
ease Research Center) and cultured in Dulbecco Modiﬁed Eagle Me-
dium (DMEM) (Gibco, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (Gibco, Grand Island, NY, USA) and
100 μg/mL penicillin–streptomycin (Gibco, Grand Island, NY, USA)
at 37 °C in a humidiﬁed atmosphere containing 5% CO2. Used
miRNAs were purchased from Ambion (Ambion, Austin, TX, USA)
and followed the manufacturer's protocol. Two kinds of miRNA are
used in this study; Let-7a mimic (cat#, 4464066; sassy ID,
MC10050) and Let-7a inhibitor (cat#, 4464084; assay ID, MH
10050). The expression and inhibition level was validated with neg-
ative (cat#, 4464058) and positive-control miRNA (cat#, 4464062)
and their time-dependent proﬁle was performed also. The cells
were cultured for 2 days and were then treated with miR-Let-7a
and miRNA negative control for each group. The cells were treated
with lipopolysaccharide (LPS [1μg/mL]) and anti-Let-7a (Ambion,
Austin, TX, USA) for 48 h after miRNA treatment; proteins and
RNAs were obtained from these cells 24 h later.
Fig. 5. Prevention of BDNF decrease by over-expressing Let-7a. (A)Western blotting showed that the protein level of BDNFwas evidently decreased in the LPS treatment group compared
to the normal control group. The protein level of BDNF was increased in miR-Let-7a with LPS treatment group compared with the only LPS treatment group. The bar graph shows the
quantiﬁcation of BDNF in all groups. β-Actin was used as an internal control. Data are expressed as mean ± S.E.M. *p b 0.05. #p b 0.05, comparison to LPS only treated group.
(B) Immunoﬂuorescent staining conducted to check BDNF expression. LPS stimulated microglia shows decreased expression of BDNF compared to the normal control microglia. MiR-
Let-7a promotes the BDNF expression in LPS treated microglia. Scale bar: 200 μm, 4′,6-diamidino-2-phenylindole (DAPI): blue, BDNF: green. Normal: normal control group, LPS: LPS
(100 nM) treatment group, LPS + Let-7a: miR-Let-7a mimic with LPS (100 nM) treatment group.
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In order to determine the level of nitrite production in the BV2 mi-
croglia cultures, the supernatant (100 μL) of each sample treated with
miRNA-Let-7a, microRNA negative control, or LPS was transferred to
96-well plates. The Griess reagents (100 μL) were added to the plate
and incubated for 15 min at room temperature (RT). Subsequently,
the absorbance was measured at 540 nm. Standards were prepared
with nitrite solution instead of the sample. The nitrite concentration in
the sample was calculated by comparing the absorbance of the sample
with a nitrite standard curve.4.3. Western blot analyses
Proteinwas extracted fromBV2microglia cultures, and equal amounts
(50 μg) were electrophoresed on 10%–12% SDS-polyacrylamide gels. Sep-
arated proteins were electrotransferred to immunobilon-NC membranes
(Millipore, Massachusetts, MA, USA), which were blocked for 1 h at RT
with 5% skim milk in Tris-buffered saline and 0.1% Tween-20 (TBST).
The primary antibodies used were BDNF (1:2000, Abcam, Cambridge,UK), cleaved caspase-3 (1: 2000, Santa Cruz, CA, USA), and β-actin
(1:1000, Santa Cruz, CA, USA). Blots were incubatedwith the primary an-
tibodies overnight at 4 °C.Membraneswerewashed 3 times (5min each)
with TBST. The secondary antibodies were anti-rabbit and anti-mouse
(1:2000, New England Biolabs, Ipswich, MA, USA) and were incubated
for 1 h at RT. After washing with TBST (0.05% Tween 20) 3 times, immu-
noreactive signals were detected using chemiluminescence and an ECL
detection system (Amersham Life Science, Buckinghamshire, UK) with
the LAS 4000 program.
4.4. Reverse transcription-PCR (RT-PCR)
To examine the expression of iNOS in BV2 cells under LPS induced
inﬂammation condition, RT-PCR was performed using iNOS primers.
Brieﬂy, samples were lysed with TRIzol reagent (Invitrogen, Carlsbad,
CA, USA), and total RNA was extracted according to the manufacturer's
protocol. cDNA synthesis from mRNA and sample normalization were
performed. PCR was performed using the following thermal cycling
conditions: 10 min at 95 °C; 35 cycles of denaturing at 95 °C for 15 s,
annealing for 30 s at 70 °C, elongation at 72 °C for 30 s; ﬁnal extension
for 10 min at 72 °C, and held at 4 °C. PCR was performed using the
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CAGCAGC, reverse (R): GCCTGTCAGAGCCTCGTGGCTTTGG, GAPDH (F):
GGCATGGACTGTGGTCATGAG, (R): TGCACCACCAACTGCTTAGC. PCR
products were electrophoresed in 1.5% agarose gels and stained with
ethidium bromide.
4.5. Quantitative real time-PCR
To examine the amount of IL-10, IL-6 and IL-4 mRNA in BV2 cells
under LPS-induced inﬂammation conditions, quantitative real time-
PCR was performed using IL-10, IL-6 and IL-4 primers. Total cellular
RNA was extracted from the BV2 microglia cells using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to themanufacturer's instruc-
tions. Poly (A) was added using poly (A) polymerase (Ambion, Austin,
TX, USA). One Step SYBR® Prime Script TM RT-PCR Kit II (Takara,
Japan) was used to conduct qRT-PCR. PCR was performed using the fol-
lowing primers (5′ to 3′); IL-10 forward (F): CCAAGCCTTATCGGAAAT
GA, reverse (R): TTTTCACAGGGGAGAAATCG, IL-6 (F): AACGATGATG
CACTTGCAGA, (R): CTCTGAAGGACTCTGGCTTTG, IL-4 F: TCAACCCCCA
GCTAGTTGTC, R: TGT TCTTCGTTGCTGTGAGG, GAPDH F: GGCATGGACT
GTGGTCATGAG, R: TGCACCACCAACTGCTTAGC. Denaturing was carried
out at 95 °C for 3 min; 40 cycles of 95 °C for 20 s; annealing at 60 °C for
20 s, and extension at 72 °C for 20 s. At each extension step at 72 °C,ﬂuo-
rescence was detected at 585 nm. The expression of IL-10, IL-6, and IL-4
was assessed using anABI prism7500 Real-Time PCR System (Life Tech-
nologies Corporation, CA, USA) and analyzedwith comparative Ct quan-
tiﬁcation. GAPDHwas ampliﬁed as an internal control. TheΔCt values of
GAPDH were subtracted from the Ct values of the IL-10, IL-6 and IL-4
genes (ΔCt). The ΔCt values of LPS-treated or miRNA-transfected cells
were compared with the ΔCt values of untreated normal microglia
BV2 cells. The fold change of each transcript was calculated with
method from2−ΔΔCt and the valueswere presented by relative quantity
(RQ).
4.6. TaqMan assay for miRNA
For quantitative analysis of miR-Let-7a, reverse transcription (RT)
wasﬁrst performed using the TaqManMicro RNA Reverse Transcription
kit (Applied Biosystems, Waltham, Massachusetts, USA) according to
the manufacturer's instructions with total RNA of 10 ng. PCR reactions
were then performed according to the manufacturer's instructions to
quantitate the expression levels ofmiRNA-Let-7a using TaqManUniver-
sal PCRMaster Mix, No Amp Erase UNG (Applied Biosystems, USA), and
TaqMan microRNA assay (Applied Biosystems, Waltham, Massachu-
setts, USA) for the miR-Let-7a of interest. PCR ampliﬁcation was per-
formed in ABI 7500 Real Time PCR (Bio Rad, Philadelphia, PA, USA) at
95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for
60 s. PCR incubation proﬁle was extended to 40 cycles for miR-Let-7a.
The differential expression level was analyzed with ddCt method. Each
miRNA expression level was presented to relative quantity (RQ) to NC
normalized with U6. PCR reactions were performed in triplicate. MiR-
Let-7a expression was normalized to the expression of U6.
4.7. Immunocytochemistry
The expression of cleaved caspase-3, CD206, CD68, and BDNF in BV2
cells was examined by immunocytochemistry. Cells in all experimental
groups werewashed three times with PBS, ﬁxedwith 4% paraformalde-
hyde for 3 h, and then washed with PBS. BV2 cells were permeabilized
with 0.025% Triton X-100 and blocked for 1 h at RT with dilution buffer
(Invitrogen, Carlsbad, CA, USA). Primary antibodies, anti-rabbit-CD206
(1:500, Santa Cruz, CA, USA), and anti-rabbit-cleaved caspase-3
(1:500, Santa Cruz, CA, USA), anti-rabbit-BDNF (1:500, Abcam, Cam-
bridge, UK), or anti-mouse-CD 68 (1:500, Millipore, Massachusetts,
MA, USA) were prepared in dilution buffer, added to samples, and incu-
bated for 3 h at RT. Primary antibody was then removed, and cells werewashed 3 times for 3 min each with PBS. Next, samples were incubat-
ed with Rhodamine-conjugated goat anti-rabbit (1:200, Jackson
Immunoresearch), or Texas red-conjugated donkey anti-mouse
(1:200, Jackson Immunoresearch) for 2 h at RT. Cells were washed
again three times for 3 min each with PBS and stained with 1 μg/mL
4′,6-diamidino-2-phenylindole (DAPI) (1:100, Invitrogen, Carls-
bad, CA, USA) for 10 min at RT. Fixed samples were imaged using
a Zeiss LSM 700 confocal microscope (Carl Zeiss, Thornwood, NY,
USA).
4.8. Statistical analysis
Statistical analyses were carried out using SPSS 18.0 software (IBM
Corp., Armonk, NY, USA). All data are expressed asmean±S.E.M. Signif-
icant intergroup differences were determined by one-way analysis of
variance (ANOVA) followed by Bonferroni post hocmultiple comparison
test. Statistical signiﬁcance with the LPS treatment group was deter-
mined by t-test. Each experiment included 3 replicates per condition.
Differences were considered signiﬁcant at p b 0.05 (*) or p b 0.001 (**).
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